Please login to the form below
lixisenatide
This page shows the latest lixisenatide news and features for those working in and with pharma, biotech and healthcare.
Sanofi wins EU approval for new diabetes combination Suliqua
The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is
Latest news
-
Sanofi launches insulin combo Soliqua in US
Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination Xultophy (insulin degludec/liraglutide), which had been expected to launch first but was delayed by an extension
-
FDA clears rival diabetes combos from Sanofi and Novo Nordisk
Adlyxin/Lyxumia (lixisenatide).
-
Gilead's hepatitis B virus treatment set for European approval
Suliqua, an insulin glargine and lixisenatide combination therapy, has been backed for the treatment of adults with type 2 diabetes. ... Sanofi's lixisenatide-only drug Lyxumia has been on the market in Europe since 2013 and was approved in the US by the
-
Sanofi trumpets new IGlarLixi data after regulatory delay
Lyxumia (lixisenatide) - helped more patients with type 2 diabetes reach post-prandial glucose targets than Lantus.
-
Sanofi loses lead on diabetes combo IGlarLixi after FDA delay
Lyxumia (lixisenatide), and has extended its review period by three months.
More from news
Approximately 12 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Interview: Pierre Chancel, Sanofi Diabetes
Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
David Horn Solomon takes the helm of Akari Therapeutics
David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by
-
Sanofi appoints general manager UK
Prior to this, Fry served as global project leader for Lixisenatide at Sanofi's diabetes unit, having moved from TMC Pharma where he served as vice president of medical.
-
Roche’s Torsten Hoffmann to join Zealand Pharma
Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it as Lyxumia for the treatment of type 2 diabetes.
-
Agneta Svedberg appointed COO at Zealand Pharma
The appointment comes at crucial time for Zealand, with its diabetes partnership with Sanofi set to pay off as the big pharma company gears up to launch Lyxumia (lixisenatide) this year.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
